Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/166211
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSánchez-López, E. (Elena)-
dc.contributor.authorEsteruelas Navarro, Gerard-
dc.contributor.authorOrtiz Rodrigo, Alba-
dc.contributor.authorEspina García, Marta-
dc.contributor.authorPrat Aixelà, Josefa-
dc.contributor.authorMuñoz Juncosa, Montserrat-
dc.contributor.authorCano Fernández, Amanda-
dc.contributor.authorCalpena Campmany, Ana Cristina-
dc.contributor.authorEttcheto Arriola, Miren-
dc.contributor.authorCamins Espuny, Antoni-
dc.contributor.authorAlsafi, Zaid-
dc.contributor.authorSouto, Eliana B.-
dc.contributor.authorGarcía López, María Luisa-
dc.contributor.authorPujol Cubells, Montserrat-
dc.date.accessioned2020-06-18T09:01:41Z-
dc.date.available2020-06-18T09:01:41Z-
dc.date.issued2020-04-10-
dc.identifier.issn2079-4991-
dc.identifier.urihttp://hdl.handle.net/2445/166211-
dc.description.abstractOcular inflammation is one of the most prevalent diseases in ophthalmology, which can affect various parts of the eye or the surrounding tissues. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, are commonly used to treat ocular inflammation in the form of eye-drops. However, their bioavailability in ocular tissues is very low (less than 5%). Therefore, drug delivery systems such as biodegradable polymeric PLGA nanoparticles constitute a suitable alternative to topical eye administration, as they can improve ocular bioavailability and simultaneously reduce drug induced side effects. Moreover, their prolonged drug release can enhance patient treatment adherence as they require fewer administrations. Therefore, several formulations of PLGA based nanoparticles encapsulating dexibuprofen (active enantiomer of Ibuprofen) were prepared using the solvent displacement method employing different surfactants. The formulations have been characterized and their interactions with a customized lipid corneal membrane model were studied. Ex vivo permeation through ocular tissues and in vivo anti-inflammatory efficacy have also been studied.-
dc.format.extent24 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/nano10040720-
dc.relation.ispartofNanomaterials, 2020, vol. 10, num. 4, art. 720-
dc.relation.urihttps://doi.org/10.3390/nano10040720-
dc.rightscc-by (c) Sánchez-López E. et al., 2020-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.subject.classificationSistemes d'alliberament de medicaments-
dc.subject.classificationAgents antiinflamatoris-
dc.subject.classificationOftalmopaties-
dc.subject.otherDrug delivery systems-
dc.subject.otherAntiinflammatory agents-
dc.subject.otherOphthalmopathies-
dc.titleDexibuprofen biodegradable nanoparticles: one step closer towards a better ocular interaction study-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec702031-
dc.date.updated2020-06-18T09:01:41Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid32290252-
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
702031.pdf5.45 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons